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Abstract 29 
The interdisciplinary EC consortium (the PEGASUS project) aimed to examine the issues 30 
raised by the development, implementation, and commercialisation of genetically modified 31 
(GM) animals, and derivative foods and pharmaceutical products. The results integrated 32 
existing social, (including existing public perception) environmental and economic knowledge 33 
regarding GM animals in order to formulate policy recommendations relevant to new 34 
developments and applications. The use of GM in farmed animals (aquatic, terrestrial, and 35 
pharmaceutical) was mapped and reviewed. A foresight exercise was conducted to identity 36 
future developments. Three case studies (aquatic, terrestrial, and pharmaceutical) were 37 
applied to identify the issues raised, including the potential risks and benefits of GM animals 38 
from the perspectives of the production chain (economics and agri-food sector) and the life 39 
sciences (human and animal health, environmental impact, animal welfare, and sustainable 40 
production). Ethical and policy concerns were examined through application of combined 41 
ethical matrix method and policy workshops. The case studies were also used to 42 
demonstrate the utility of public engagement in the policy process. The results suggest that 43 
public perceptions, ethical issues, the competitiveness of EU animal production, and risk-44 
benefit assessments that consider human and animal health, environmental impact, and 45 
sustainable production need to be considered in EU policy development. Few issues were 46 
raised with application in the pharmaceutical sector, assuming ethical and economic issues 47 
were addressed in policy, but the introduction of agricultural GM animal applications should 48 
be considered on a case-by-case basis.  49 
Key words 50 
Genetically modified animals, Pharmaceutical, Food, Societal acceptance, Economic impact, 51 
Risk-benefit assessment. 52 
Highlights 53 
• Public perceptions of GM animals are generally more negative than towards GM                54 
plants. 55 
• GM animals are perceived more negatively if used for food rather than for       56 
            pharmaceuticals. 57 
• A case-by-case assessment of the risks and benefits of GM animals is warranted. 58 
• EU governance systems are reasonably well-prepared. 59 
• Clarity is needed on how different publics are engaged in GM animal technology.  60 
• Public and stakeholder engagement exercises can be useful tools for informing policy  61 
            development. 62 
  63 
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1. Introduction 64 
 65 
Food products derived from genetically modified (GM) animals have not yet entered the 66 
European market. None-the-less, the on-going discussion about GM crops [1], and the 67 
developing debate about the safety and ethics of foods and pharmaceutical products 68 
produced by both GM animals and plants, have provoked varying views across different 69 
sectors of society (e.g., see [2]; [3]; [4]). At the time of writing, while no GM animals have 70 
been approved for food use in Europe or the US (see also [5]), this is not the case for 71 
pharmaceuticals derived from GM animals ([6]; [7]; [8]). Medical application is more 72 
widespread internationally, with research focusing on applications of GM animals in the 73 
study of gene function and human diseases [6], or as a source of therapeutic human 74 
antibodies [9].   75 
 76 
The use of GM animals in agriculture may potentially present greater challenges than   77 
process and products, the relative value of the product is less within the agricultural sector, 78 
and animal welfare concerns related to farmed animals may  arise. In addition, production of 79 
GM animals for agricultural purposes is a less efficient process than is the case for medical 80 
applications (e.g., [10]; [11]; [12]; [13). These potential barriers to commercialisation have 81 
frustrated many scientists keen to bring applications to the commercialisation stage ([14]; 82 
[15]). Independent of whether a specific application of GM animal is licenced for use in a 83 
particular region or country, regulators may also need to consider the possibility that agri-84 
food applications of GM animals may enter the food supply chain through imports from 85 
overseas [16]. For example, the EU is the world’s largest international trading block for food 86 
commodities [17]. Importing goods from countries and regions which operate different 87 
regulatory approaches to commercialisation of GM animals [8] may result in accidental or 88 
fraudulent inclusion of GM animals in the European food supply chain. Progress in reducing 89 
or eliminating potential inconsistencies across jurisdictions, and harmonising international 90 
regulations, is slow. Despite this, commercialisation of the products of GM animals, whether 91 
applied to agriculture or pharmaceutical production, is fast becoming a reality. Appropriate 92 
evidence-based governance frameworks, which take account of all relevant factors, are 93 
required, and these need to be contextualised by understanding of societal responses to 94 
emerging technologies such as GM animals used in agricultural and pharmaceutical 95 
production. This information is needed to optimize and regulate strategic development of, 96 
and communication about, GM animals, as well as to develop and refine commercialisation 97 
strategies associated with specific GM products (see, inter alia, [18]; [19]). The issue of 98 
whether alternative technological approaches can be applied to reach the same goals also 99 
needs to be considered [19].  100 
 101 
An overview of the current European regulatory framework for GM animals is provided by 102 
[8]. In summary, guidance for specific risk assessments for food/feed applications and the 103 
environment is provided by the European Food Safety Authority (EFSA), whereas those for 104 
pharmaceutical applications fall within the remit of the European Medicines Agency (EMA). 105 
In addition, DG SANCO has a central role in governance, in particular with respect to risk 106 
management, with the addition of animal specific legislation in the framework of the 107 
Community Animal Health Policy (CAHP) including animal welfare legislation. Partly in 108 
response to societal negativity towards GM technology within Europe, the European 109 
Commission has adopted a more precautionary approach to introductions in agriculture [20], 110 
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including mandatory labelling of GM food products [21]; [22]. This has, in turn, resulted in 111 
implications for international trade [23]; [24]. 112 
 113 
The objective of the Pegasus project was to provide support for European policy regarding 114 
the development, potential implementation, and commercialisation of GM animals, both 115 
terrestrial and aquatic. The research drew on the results of research originating within both 116 
the life- and socio-economic sciences, which assessed the potential risks and benefits of the 117 
development and application of GM animal technology. In addition, ethical analyses were 118 
applied to ensure that such evidence is provided for policy development. The research 119 
synthesised this evidence  into concrete and actionable suggestions for policy outcomes 120 
relevant to Europe, as well as considering policies relevant to the EU’s major trading 121 
partners. To the authors’ knowledge, this is the first time interdisciplinary evidence relevant 122 
to European policy development has been collated in the area of the use of genetically 123 
modified animals for food and pharmaceutical developments. The issues raised by the 124 
development and use of GM animals will now be considered from both life science and 125 
socio-economic perspectives. Ethical issues and policy dimensions will also be considered. 126 
Future policy implications will be identified from the synthesis of these different perspectives. 127 
128 
5 
 
Background 129 
 130 
The definition of “genetic modification” (“GM”) aligns with that provided by Directive 131 
2001/18/EC [25]. This definition includes techniques for introduction of recombinant DNA, 132 
transfer of heritable material through various artificial ways, and fusion of cells of different 133 
organisms that cannot be crossed in nature. In addition, there are various techniques for 134 
cloning animals, including embryo splitting, and the transfer of a nucleus from a donor cell 135 
into an enucleated oocyte. These techniques are not usually included in the same category 136 
as genetically modified organisms (GMOs) by European regulators. This is not necessarily 137 
the case in other regulatory frameworks (e.g., the cloning of organisms new to New Zealand 138 
from imported cell materials [26]). 139 
 140 
The  potential risks and benefits of GM animals, whether applied to food production or to 141 
other areas of application, such as pharmaceutical “farming”, have been recognised by 142 
governments, industry and non-governmental organizations (NGOs) as an important 143 
determinant of their potential future development (e.g., [27]; [28]; [29]; [30]; [31]). Substantial 144 
resources have been invested in national and regional initiatives relating to research and 145 
safety assessment of GM animals with the aim of managing human and animal health risk, 146 
and environmental impacts ([32]; [5]; [33]; [34]). Resources have also been dedicated to the 147 
analyses of activities which focus on the ethical dimensions of using GM animals in the food 148 
production ([35]; [12]) and pharmaceutical [6] sectors. As in any novel area of science, 149 
progress in the field of GM animals - from basic research, through the experimentation and 150 
testing phases, to the positioning of the final application in the marketplace and the 151 
development of the associated commercialisation strategy - is dependent on both the safety 152 
and the cultural acceptability of the processes and the products concerned [36]. 153 
 154 
An extensive literature regarding public perceptions and other socio-economic aspects of 155 
GM animals applied to food production and other areas of application is available. Similarly, 156 
there are many scientific publications relating to technological advances and potential 157 
economic impacts. This information cannot be translated into concrete policy support unless 158 
different disciplinary perspectives can be integrated into a coherent evidence base from 159 
which policy can be developed. The Pegasus projects adopts  multidisciplinary approach, 160 
drawing on expertise from both the social and life sciences, to integrate scientific information 161 
into evidence for policy development, which can then be translated into policy options. 162 
Ethical dimensions and insights into the evolving international policy landscape must be 163 
taken into account in this process.164 
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The potential risks and benefits of GM animals from a life-science perspective 165 
 166 
Realistic scenarios representing technological applications of GM that may enter the market 167 
in the future were developed through a combination of literature review, data mining 168 
activities, and expert consultation with industry and academic specialists. Data sources 169 
included the scientific literature, and data from patents, and experimental permits [37]. The 170 
results suggested that the techniques available to generate GM animals have improved 171 
considerably, and so development costs are no longer represent a major barrier to the 172 
development of transgenic animals. In particular, the cost of genetically modifying larger 173 
animals is no longer prohibitive, as was the case in the past. For example, models for the 174 
study of human diseases can now utilise GM pigs as well as GM mice, allowing for more 175 
sophisticated analysis ([12]; [37]; [38]). GM animals have also been used to develop organs 176 
for xenotransplantation to humans, although these are not yet licensed for use [39]. 177 
 178 
Advances in research into GM farm animals have resulted in foods derived from these 179 
animals having enhanced quality or production yields [12], or improved nutritional value 180 
(e.g., [40]; [41]). A major problem in conventional breeding remains that of animal diseases, 181 
which results in animal losses, animal welfare problems and threats to human health. 182 
Chickens which do not pass on influenza virus to other chickens [42], and (potentially) pigs 183 
resistant to Aujeszky disease ([43]; [44]) provide good examples of breeding improvements 184 
resulting from animal GM. Foods may be changed to meet the needs of individuals with 185 
specific dietary requirements, such as the modification of milk fat composition to enhance 186 
fatty acid content [45]. Developments are frequently intended to improve food security or 187 
human health, although the benefits and long-term impacts on agricultural sustainability are 188 
difficult to predict [46]. The most technologically advanced projects are related to the 189 
expression of bioactive compounds such as human lactoferrin in bovine milk ([47]; [48]), and 190 
the production of meat enhanced with omega-3 fatty acids through the expression of 191 
roundworm desaturase gene in transgenic pigs [49]. The most direct application of GM 192 
animals, which may bring benefits to public health, is the production of therapeutic 193 
recombinant proteins ([6]; [9]). For example, GM animals have been used for production of 194 
specific proteins for treatment of various health problems such as blood disorders 195 
(thrombosis and haemophilia), hereditary angioedema, osteoporosis, and emphysema [50]. 196 
 197 
The production of pharmaceuticals from GM animals is relatively efficient, but rarely applied 198 
in a commercial context by pharmaceutical companies. This, in part, may be a consequence 199 
of industry concerns about the societal acceptance of GM animals. However, there may be 200 
other commercial reasons underlying this observation. Pharmaceutical companies can 201 
potentially be in competition to produce pharmaceutical proteins. For this reason, individual 202 
companies may be disincentivised regarding the promotion of the production of 203 
pharmaceutical proteins by GM animals, which may broaden competitors’ access to the 204 
same compounds. Despite this, there is greater investment in the use of GM animals in the 205 
medical and pharmaceutical sectors compared to the food sectors, with three major 206 
countries leading developments (China, Argentina and the USA) [15]. In comparison, the EU 207 
is less advanced scientifically [8]. The technical potential and scientific resources for the 208 
production of GM animals in the EU is high, but the number of supported projects remains 209 
very low compared to those on other regions of the world.   210 
 211 
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Some animal welfare issues associated with GM animals have been identified, which may 212 
militate against development of GM animal technology. These include reproduction problems 213 
originating from in vitro procedures such as large offspring syndrome, (although it should be 214 
noted that uncertainties in the risk assessment arise from the limited number of studies 215 
available, the small sample sizes investigated and the absence of a uniform approach to 216 
allow all the relevant issues to be addressed [51]), and requirements for special feeding and 217 
restricted rearing conditions [52]. Some welfare issues are particularly problematic, e.g. 218 
those related to animal welfare requirements such as free rearing, mating and access to 219 
feed [53]. Agrobiodiversity may be potentially reduced as breeding will involve fewer species 220 
and breeds. A further concern relates to the possible privatisation of genetic resources due 221 
to the application of intellectual property rights. Improved food security through increased 222 
production efficiency may be facilitated by the development of GM animals, assuming this is 223 
not compromised, by, for example, reduced availability of genetic resources.  224 
 225 
A further issue relates to environmental impact (e.g., unintended environmental release of 226 
animals) which may be less controllable for high profligacy species such as fish [51]. In the 227 
areas of both pharmaceutical and food production, contained production facilities may be 228 
required to prevent such occurrences. In addition, the implementation of effective traceability 229 
systems is required to ensure that GM animals and their products can be identified within 230 
supply chains. The production of recombinant proteins is regulated under conventional 231 
pharmaceutical guidelines [54]. 232 
 233 
The main risk assessment concern, which can be identified when considering the use of any 234 
GM organism for food or feed production is food safety, is the potential for introduction of 235 
allergens or toxins [5]. Risk assessment should be conducted on a case-by-case basis using 236 
a comparative approach, and due consideration should be taken of differences between 237 
different types of animals and their putative area of application. Thus not all assessments 238 
would apply to all cases, at least not in the agri-food sector [55].  239 
 240 
A broad range of relevant issues were assessed in the context of the three specific case 241 
studies, based on  GM animals relatively close to commercialisation (Table 1). The cases 242 
were selected to represent aquatic versus terrestrial GM animals, and drawn from animals 243 
used for food versus pharmaceutical production. 244 
………………………………………… 245 
Table 1 about here 246 
………………………………………… 247 
 248 
There are differences in the amount of data available to assess risks and benefits within 249 
cases. For example, the available data suggest that the contained farming of GM salmon 250 
poses limited environmental risks [56], whereas there are fewer data available regarding the 251 
GM rabbit case (e.g., associated with potential environmental impact following deliberate or 252 
accidental environmental release [52]). In addition, there are no data on health and welfare 253 
issues specific to the case of GM rabbits used for production of polyclonal antibodies. This is 254 
problematic given concerns related to the large numbers of animals sacrificed, the 255 
procedures such as caesarean section required in reproductive processes, and actions such 256 
as handling and restraint that can cause distress.   257 
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Public perception of GM animals and the food and pharmaceutical products derived 258 
from them. 259 
 260 
A systematic review of the published literature on public perceptions of GM animals was 261 
conducted. This resulted in two subsequent analyses. In the first, a meta- aggregated 262 
published data1 on public perceptions of GM animals and plants, allowing changes in 263 
perceptions and attitudes in time, and in different regions, to be identified [10]. Seventy 264 
papers yielded data of appropriate quality to be included in this meta-analysis. In summary, it 265 
was found that both risk and benefit perceptions increased with time (from the early 1990s 266 
until 2011), independent of the region in which the data were collected. Ethical concerns, 267 
and perceptions of unnaturalness, were found to influence societal and/or consumer 268 
acceptance. However, not all these dependent variables were included in all studies 269 
reviewed. As a consequence, an aggregated analysis of the impact of ethical concerns and 270 
unnaturalness on risk and benefit perceptions was not possible, although trends in time and 271 
between regions within dependent variables could be analysed. In addition, trust (both in 272 
regulatory institutions and in information about GM animals) was identified by researchers as 273 
being highly relevant to acceptance. In this case, the application of different methodological 274 
approaches applied to measuring trust made it inappropriate to integrate research results 275 
using meta-analytic approaches, to the extent that statistically significant differences 276 
between regions and trends in time could not be reliably assessed. Other important results 277 
related to comparisons between different sectors of application. Medical applications were 278 
consistently better accepted than those related to food production. Regional differences 279 
were observed, such that perceptions of risk were higher, and benefit perceptions lower, in 280 
Europe compared to North America and South-East Asia, while the converse was true of 281 
ethical concerns, which were lower in Europe. (See [10] for details of the quantitative 282 
analysis and significance tests).There were few data available from BRIC countries2 (Brazil, 283 
Russia, India, China), nor South America and Sub-Saharan Africa.  284 
 285 
The second analysis focused on all papers identified in the systematic review which included 286 
data on consumer perceptions of GM animals, independent of whether these yielded data 287 
suitable for meta-analysis [11]. Forty-two such papers were included3. The main findings of 288 
the papers were collated and coded according to superordinate themes. Most data were 289 
collected in North America (in particular the US) and Europe, with some data being collected 290 
in South-East Asia and Australia. Two papers reported on consumer attitudes in either China 291 
or India. As was found in the meta-analysis, attitudes were less positive towards GM applied 292 
to animals compared to plants, and for GM animals applied to food relative to other sectors. 293 
Higher perceptions of benefit tended to offset risk perceptions, in both the food and medical 294 
sectors. Attitudes towards GM fish applied in the agricultural sector (specifically salmon as 295 
no other public perception data were identified through the paper selection process used in 296 
the review) were more positive than towards other types of animal.   297 
 298 
  299 
                                               
1
 For practical reasons, only English language peer reviewed publications were included. 
2
 The authors suspect that such a literature may be available in local languages, for example in China. 
However these publications were not available for pragmatic reasons related to language and 
limitations of the data bases accessed (Scopus and Web of Science).  
3
 The results of the systematic reviews conducted within Pegasus are published in [10] and [11]. The 
reader is referred to these documents for a full list of the papers contributing to systematic reviews. 
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The economic dimension of GM animals in production 300 
 301 
The economic implications of GM animals and their applications from a production chain 302 
perspective (i.e. feed industry, breeding industry, primary sector, processing industry, and 303 
pharmaceutical industry) were considered. It should be noted that relevant economic data 304 
were difficult to obtain, given that the products of GM animals have yet to be commercialised 305 
within either the pharmaceutical or agri-food sectors. In the course of the project, one 306 
pharmaceutical product from GM goats, ATryn®, was released onto the market [57], which 307 
may provide relevant data for follow-up economic studies. An initial scoping study identified 308 
key issues from the literature [58].  Broad consensus emerged insomuch as developments in 309 
GM animals were expected to result in economic benefits for farmers, processors and 310 
consumers, in particular, but not exclusively, in the area of pharmaceutical production [59]; 311 
[60]; [61]. However, empirical data were not available to substantiate these claims. For this 312 
reason, scenario analysis was applied, which permitted assessment of the economic 313 
impacts of potential ‘futures’ associated with different applications of GM animals. Scenario 314 
analysis has been widely used to deal effectively with the many uncertainties that surround 315 
the future of strategic decision-making [62], including that associated with technology 316 
assessment [63].  317 
 318 
The scenario analysis was applied across the case studies. Analogies were identified across 319 
the different case studies, even if the products considered were very different [64] (see table 320 
1).  321 
………………………. 322 
Table 1 about here 323 
……………………….. 324 
 325 
The results of the analysis suggest that production costs will decrease as a consequence of 326 
the use of GM animals in both food and pharmaceutical production, which will potentially 327 
increase producers’ and consumers’ acceptance and subsequently increase global 328 
production. However, consumer acceptance of products, in particular food products, will act 329 
to increase production costs. Given that public acceptance of pharmaceutical products is 330 
likely to be higher than for food, economic advantage is most likely to be associated with the 331 
pharmaceutical sector. It was concluded that policy makers should explicitly consider taking 332 
socio-economic aspects associated with the introduction of GM animals into the evaluation 333 
and authorisation processes linked to new applications. In addition, care should be taken to 334 
ensure that the socio- economic benefits of GM animals are distributed equitably across 335 
countries and populations. Small to medium enterprises which do not (or are unable to) 336 
adopt GM animal technologies may need to be protected, not least in order to protect the 337 
autonomy of consumer choice.  338 
 339 
Analysis of stakeholders’ positions and ethical judgements 340 
 341 
The ethical issues raised by the development and application of genetic modification were 342 
considered through a process of stakeholder consultation utilising dedicated workshops in 343 
order to identify values and principles underlying the stakeholder’s perceptions of GM 344 
animals. Five stakeholder workshops were convened, involving policy, industry, producer, 345 
and NGO representatives. All workshops were entitled “Examining the social and ethical 346 
issues raised by genetically modified animals; Examining the key issues”. The first three 347 
workshops focused on mapping stakeholder views and were held in three European 348 
countries, (Germany, N=6 stakeholders (see [65]); Norway, N=9 stakeholders (see [66]); and 349 
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the UK, N=12 stakeholders (see [67]). A fourth workshop had a less diverse stakeholder 350 
membership, involving 7 participants with an EU policy profile, and was held in Brussels (see 351 
[68]). The final workshop was held in Hyderabad, India, and provided a non-EU perspective 352 
in a country which represents an important trading partner for the EU, and where there is 353 
also controversy associated with GM animals. Seventeen stakeholders were involved the 354 
Hyderabad event. The Ethical Matrix approach was selected as an appropriate method to 355 
consult stakeholders [69]. This has been demonstrated to be a successful approach to 356 
understanding stakeholder ethical issues associated with GM animals in previous 357 
investigations (e.g. [70]; [71]). In brief, this approach is intended to support individuals when 358 
making ethical decisions, particularly regarding ethical issues associated with new 359 
technologies. Four ethical principles are normally addressed. These are to do good 360 
(beneficence), to do no harm (maleficence), the principle of autonomy (providing the 361 
freedom of choice) and justice (ensuring the equitable distribution of costs and benefits). It 362 
was not feasible to invite stakeholders to discuss all three cases in great detail within the 363 
workshops, given specific circumstances and the amount of information pertaining to each. 364 
Deliberation needed to be initially limited to one application, although broader questions 365 
were raised in the final discussion sessions. A decision was made to use the workshops to 366 
explore and map ethical issues arising from the use of GM salmon. This was pertinent 367 
because the European Food Safety Authority (EFSA) appeared to be most advanced with its 368 
policy preparations for GM fish [72], and the high-profile application to allow the 369 
commercialisation of a GM salmon was being considered by the USA’s Food and Drug 370 
Administration at the time the workshops were being held [73].   371 
 372 
Most of the issues discussed relative to GM salmon were deemed to be equally relevant to 373 
other species of GM animals [74], and were identified across the different workshops. These 374 
will now be briefly discussed. The notion of a single instance of the technology acting as a 375 
‘door-opener’ to future technology development and commercialisation was identified as 376 
relevant, irrespective of species modified. Some participants suggested that each application 377 
should be ‘treated individually,’ with particular regard to its purpose; for example, 378 
applications intended to enhance food security may be regarded as more necessary and 379 
ethically justifiable than those applied for ornamental purposes (e.g., the “Glofish”4). It was 380 
argued that GM fish present fundamentally different issues to terrestrial animals, because (a) 381 
they present a higher risk of escape, and are almost impossible to contain once they are in 382 
the external environment and (b) society tends to have relatively fewer animal welfare 383 
concerns for fish. However, welfare concerns were prominent across all species of animal 384 
considered. The discussions suggested that what is deemed to be acceptable is informed 385 
not only by scientific data, but also by ethical boundaries (e.g., what level of potential 386 
suffering is deemed acceptable). Many workshop participants highlighted and discussed the 387 
knowledge gaps and uncertainties related to research and use of GM animals, for example 388 
in relation to animal welfare, environmental, and socio-economic implications, as well as 389 
uncertainty associated with these. Participants indicated that future interdisciplinary research 390 
is required to address these gaps in knowledge, acknowledging the relevance of the 391 
precautionary approach. Participants also felt it was important that the burden of proof 392 
associated with technology assessment in order to make a judgement on a licensing 393 
decision should lie with the relevant industry, and this should be supported by independent 394 
audit of industry information. 395 
                                               
4
 A GM zebrafish altered to exhibit fluorescent colours. 
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 396 
Whilst acknowledging the need to encourage industrial innovation in food production, in line 397 
with EU policies, some participants suggested that any collective decision-making process 398 
should not be rushed according to the ’politics of urgency.’ It was felt that ‘Europe’ has time 399 
to consider properly any decision to permit the introduction and or commercialisation of GM 400 
animals. If individual consumer autonomy is deemed to be important then the specifics of 401 
labelling requirements will be a central element of any licensing conditions, an observation in 402 
line with consumer perceptions and expectations, as well as a prerequisite for economic 403 
success. Stakeholders also suggested that it may be important to first reconsider 404 
conventional practices and alternative technological approaches to reach the same 405 
objectives, together with the wider management and use of natural resources [18]. In 406 
general, stakeholders did not appear to express intrinsic objections towards GM animals per 407 
se. The general focus of the discussions was on the purpose and the placement of any 408 
technology within a production system, in particular agri-food production. The primary 409 
question related to what might be the best form of technical investment, in line with the 410 
results of the economic analysis. Many stakeholders also expressed the view that 411 
consideration of socio-economic impact should be, an integral part of any technology 412 
assessment process. Finally, stakeholders suggested that more data is needed to support a 413 
number of statements about GM animals. For example, when considering the ‘grand 414 
challenges’ for modern society, such as the need to improve food security, a notable number 415 
of participants across all the five workshops felt that GM salmon technology would not 416 
address global food security needs because it is a niche product for more affluent 417 
consumers. Other technological options, or GM species, need to be considered in this 418 
respect.  419 
 420 
Policy implementation and development 421 
 422 
Methodological details of policy data-gathering are provided in [8]. In summary, the data 423 
were gathered through literature review of peer-reviewed journals and policy reports, internet 424 
searches and media stories complemented by face-to-face and phone interviews with key 425 
stakeholders. In total, 28 semi-structured interviews were conducted with participants drawn 426 
from scientific, regulatory, industry and consumer groups [15] drawn from Europe and the 427 
US. Workshops were held in collaboration with the Ethical Matrix consultations described in 428 
the previous section in order to discuss with stakeholders various policy-related issues 429 
associated with the introduction of GM animals and to identify policy gaps and policy options 430 
that need to be considered. Various policy-related issues, including regulatory needs, were 431 
discussed in order to address the aspects of the GM animal cases.  432 
 433 
An initial scoping exercise (internet and desk-based study) was used to construct a model of 434 
the main policy parameters. This theoretical framework provided the background from which 435 
the interview schedule was developed. To further understand the politics surrounding the 436 
governance of GM animals, the range of existing policy at national, (pan-) European and 437 
USA (international) levels relevant to the regulation of the GM animal field was reviewed [8]. 438 
The key national regulatory bodies and other agencies involved in the governance of GMOs 439 
were then identified. Stakeholders within these organisations were approached and 440 
interviewed regarding the complexities of GMO governance mapped. In parallel, the 441 
international organisations that have a role in GMO governance (at the risk assessment 442 
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and/or risk management stages) were identified and key stakeholders interviewed regarding 443 
governance practices associated with GM animals.  444 
 445 
The results suggest that, at the regulatory stage in the EU, existing governance structures 446 
are reasonably well prepared for GM animals. In the area of research and development, the 447 
regulations were perceived by stakeholders to be adequate, but the situation was quite 448 
different at the commercialisation stage. The level of risk communication with European 449 
citizens considered was insufficient, although there were disagreements on what to 450 
communicate and who should do it. The majority of the interviewees believed that the 451 
European Commission should lead any communication strategy on GM animals. The 452 
situation for the pharmaceutical sector was seen to be stable at the international level, but 453 
the future of GM animals in the agrifood sector varied regionally. The most significant 454 
change was seen in the USA, (which has historically been a strong proponent of GM plants). 455 
The cultural attitude of the American consumer towards GM animals (in particular in relation 456 
to ethical concerns) appeared to trigger a retreat from the food industry in its support for GM 457 
animals in production. At the same time, emerging economies, particularly China, are 458 
encouraging development in this sector. It is therefore likely that the international landscape 459 
for GM animals will differ significantly from that of GM plants.  460 
 461 
In addition to interviewing policy makers, the utility of an approach to public consultation 462 
regarding policy development, the ‘citizens’ jury,’ was assessed as a potential process to 463 
facilitate public engagement with the policy process. The consultation process utilised a 464 
‘citizens’ jury’ approach, with jurors being drawn from participants from various backgrounds 465 
[75]. The need to engage the public in the development of science and technology policy is 466 
recognised [76], and has included public engagement associated with GM policies [77]; 467 
[78].The vogue for public engagement has been criticised [79], in part due to frequent lack of 468 
goal orientation regarding how public engagement might inform policy impact, and absence 469 
of processes or mechanisms to assess the impact on policy development. This is despite 470 
such exercises being frequently commissioned with the stated aim of informing policy [80]. 471 
The result is that there has been a lack of evaluation of both the process and policy impact 472 
[79] of public engagement exercises.  473 
 474 
The main goal of the citizens’ juries was to demonstrate ‘best practice’ in public engagement 475 
in future policy regarding innovation in the area of GM animals. Two public engagement 476 
activities were conducted, in Newcastle, UK and Parma, Italy [81]5. Fifteen jurors 477 
participated in the Newcastle event, and 16 in the Parma event. They were drawn from a 478 
wide range of socio-economic backgrounds. The juries were both held over a two day 479 
weekend. Jurors were able to ‘cross-examine’ the expert witnesses (drawn from researchers 480 
in the project consortium), and were requested to develop a report making specific policy 481 
recommendations regarding an innovation strategy for GM animals applied in the 482 
pharmaceutical and food production sectors. Expert witnesses presented a “lay” version of 483 
the scientific activities of the project, together with draft policy implications. In addition, and in 484 
accordance with best practice, an independent evaluation of both the process of conducting 485 
both juries, and the impact on the final policy recommendations, was conducted [79].  486 
                                               
5
 Citizens’ juries have been used in the UK and Italy previously. See, for example, 
(http://www.parliament.uk/documents/commons/lib/research/briefings/snpc-04546.pdf), accessed 20
th
 
January 2013 for the UK, and [82] for Italy. 
13 
 
 487 
Overall, the jurors  approved of existing governance structures within Europe (for example, 488 
separation of medical and food-related GM animal governance to the European Medicines 489 
Agency, EMA, and European Food Safety Agency, EFSA, respectively). However, this 490 
observation cannot be extrapolated to all EU Member States, which may have very different 491 
socio-historical contexts associated with governance structures and implementation, and 492 
highlights the need to conduct such exercises in all areas where a particular set of policies 493 
are to be implemented. The attitudes of jury members towards GM animals applied to food 494 
production and pharmaceuticals were broadly in line with the conclusions of the public 495 
perception analysis. These results validated the use of the citizens’ jury approach as a tool 496 
to engage citizens and solicit information about their opinions regarding GM animals.   497 
The evaluation process was based on short-term participant observation during the citizens’ 498 
jury events themselves, and involved observation of the proceedings of the events as well as 499 
formal and informal discussions with witnesses, convenors and jurors. The focus for this 500 
evaluation was on the issues arising that are of relevance to an understanding of the extent 501 
to which the citizen’s juries approach fulfils the intended objectives, and, in particular, to 502 
comment on their role as a useful tool for informing policy development. 503 
 504 
The jurors in the UK perceived that the majority of the expert witnesses to be pro-GM and 505 
felt they would have liked to hear a more strongly articulated anti-GM argument. This may 506 
reflect the jurors’ expectation of being presented with two different ‘sides’ of the argument, 507 
and subsequently being asked to make a decision between them. Instead, the citizens’ jury 508 
was presented with the potential risks and benefits of GM animals, which, while allowing the 509 
jurors to come to their own mediated position, did not necessarily require an outright 510 
ascription to one extreme position or another. This may reflect a pre-existing "bias" on the 511 
part of the jurors towards controversy associated with this subject, which may have 512 
increased the intensity of the jurors’ discussions. There was a sense from the citizens’ juries 513 
that formulating policy recommendations was a particularly difficult task for the jurors. 514 
Temporal limitations restricted the time available for jurors to consider and construct policy 515 
recommendations. In addition, jurors themselves were interested to know the use of any 516 
outputs in terms of policy impact which could not be provided as the activities were designed 517 
to demonstrate the utility of the approach, not deliver evidence upon which policy could be 518 
based.  519 
 520 
Discussion  521 
Taken together, the integrated results imply that GM animals need to be considered on a 522 
case-by-case basis, independent of whether risk assessment, socio-economic impacts, or 523 
ethical issues are being considered. Due consideration should be taken of differences 524 
between different types of animals and the reasons for their modification. Not all 525 
assessments would apply to all cases, at least not for those within the agri-food sector. For 526 
example, research is needed which will enable examination of the welfare issues associated 527 
with handling and manipulating GM animals in general, although a case-by-case approach 528 
will be required as different types of animals and genetic modification may raise different 529 
welfare issues. Ensuring there is clarity regarding ethical ‘boundaries’ of decision-making 530 
processes may be an important element of any future GM animal licensing / policy process. 531 
As part of this more research into the socio-economic dimension of GM animal 532 
commercialisation, and how this contrasts with alternative approaches, may be required in 533 
order to optimise food chain and pharmaceutical benefits from innovations using both GM 534 
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and non-GM animal technologies. Issues of social equity were also identified. Risk-benefit 535 
assessments should consider the impacts on all producing countries to ensure developed 536 
countries, (for example, EU member states ), do not reap the benefits of animal GM 537 
technologies, while exporting any health, environmental or socio-economic  risks to other 538 
countries, in particular those which are economically developing.  539 
 540 
In order to promote scientific and regulatory leadership in this area, the results indicate that it 541 
is important that the EU supports research to improve techniques for the generation of GM 542 
animals and the evaluation of the potential impacts which simultaneously take due account 543 
of the preferences of European citizens. It is suggested that, as a recommendation for best 544 
practice, this may also be relevant internationally. The results suggest this may translate into 545 
prioritisation of medical applications of GM animals, at least in the initial stages of an 546 
implementation and commercialisation trajectory. Given the reticence of pharmaceutical 547 
companies and other industry stakeholders to engage in research utilising GM animals, it 548 
may be useful to initially develop innovation through public funding if pharmaceutical 549 
applications are deemed a public good. Alternatively, such research might be advanced 550 
through facilitation of public-private partnerships.  551 
 552 
An important conclusion was that the development, implementation, and (possible) 553 
commercialisation strategy for GM animals would need to assess what benefits of products 554 
are perceived to be substantial enough to outweigh perceived risks and negative attitudes. 555 
This may require research to identify information about what the public perceives to 556 
constitute a desirable benefit early enough in development to influence the design of the 557 
final product. In this context, attitudes may crystallise following the implementation of EU or 558 
international legislation, or following the commercialisation of the products of GM animals 559 
intended for consumer purchase, (in particular in the food sector, where public concern is 560 
greatest).  Further tracking of perceptions and attitudes is warranted. In addition, greater 561 
understanding of consumer and/or citizen reactions to GM food and pharmaceutical products 562 
in potential markets (e.g. in BRIC countries) and in capacity building partner countries is 563 
important in order to refine trade and capacity building agreements developed between  564 
Europe, and international trading and development partners. 565 
 566 
Labelling and consumer choice emerged as an important issue in relation to food in all 567 
regions where data were available. Although attitudes towards food related applications of 568 
GM animals appeared more positive in South-East Asia, the requirement for effective 569 
traceability and labelling was also high in this region. Following on from this, a certification 570 
system is needed to distinguish the products of GM animals from non-GM counterparts. This 571 
is a complex issue for regulators, specifically in terms of what labelling conditions and 572 
verification systems would be needed, but reflects societal expectations, and the conditions 573 
which will lead to successful economic exploitation of GM animals, in particular applied to 574 
food production. In line with current European legislation regarding other food products 575 
produced using GM, it is suggested that labels should indicate that a specific product has 576 
been produced using GM animals. Mechanisms to ensure effective traceability (e.g., through 577 
RFID tagging or other traceability testing) may be needed to develop and maintain consumer 578 
trust. It is also important to develop a labelling strategy in line with the WTO agri-food sector 579 
agreements [83]. However, GM-animal-free labelling might emerge as a private initiative 580 
adopted by some companies. Labelling should also be applied to export products to 581 
countries where there is particular consumer demand for such traceability, such as South-582 
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East Asia. Traceability systems should enable labelling to be easily applied to 583 
pharmaceutical products may also be relevant, if societal demand suggests that this is 584 
appropriate. However, the societal requirement for the introduction of stricter regulations 585 
related to traceability and labelling systems for products obtained from GM animals will act to 586 
increase production costs, which will be offset by decreased production costs overall. Price 587 
reductions have potential to increase producers’ and consumers’ acceptance, (assuming the 588 
reduction in price is passed on to the final consumer).  589 
 590 
Increased consumer acceptability is also contingent on consumers identifying personal 591 
benefits to be associated with GM animals (such as those related to health) compared to 592 
benefits to the business sector. Thus monoclonal antibodies produced using GM rabbits may 593 
be viable economically, as public acceptance of pharmaceutical products developed using 594 
GM animals will be more positive than those applied to food production.  595 
 596 
Two issues relating to socio-economic economic impact and issues of equity were identified. 597 
The first relates to small and medium enterprises (SMEs), identified as essential elements in 598 
European economic competiveness and provision of employment [84], as well as important 599 
generators of income in other parts of the world [85]. As a consequence of the introduction of 600 
foods produced using GM animals reducing the prices of associated products in regional or 601 
international markets, businesses which do not adopt the technology may become non-602 
competitive, unless they were able to charge a premium for non-GM derived equivalent 603 
products. Under these circumstances, financial or informational support to SMEs that could 604 
potentially suffer economic losses might be important to preserve the SME sector and 605 
maintain consumer choice [86]. The second relates to developing and maintaining economic 606 
equity between developed and developing countries. Specifically, the EU and other regions 607 
where GM technology is relatively highly advanced should define appropriate tools to 608 
support high-quality GM animal pharmaceutical products to be available for therapies and 609 
treatments in developing countries, in particular in relation to patent enforcement and 610 
capacity building [64]. Similar policies might apply to knowledge transfer regarding GM 611 
animals and food production. The successful implementation of such policies would require 612 
societal acceptance of pharmaceutical and food products derived from GM animals in both 613 
producer and end-user communities. Data are not available to assess local stakeholder and 614 
consumer concerns and priorities in many developing regions, research into citizen priorities 615 
and preferences within these communities may be required. If GM animals are adopted 616 
internationally, international organisations will be required to take a leading role in promoting 617 
the global harmonisation of relevant regulatory structures, in particular regarding the 618 
handling of the trade disputes that are expected to emerge may also be the responsibility of 619 
international organisations.  620 
 621 
In terms of science, the EU might encourage the definition of different baseline scenarios for 622 
various GM animal species that could be debated and agreed by the National Competent 623 
Authorities. These could be used during the risk assessment process by the European Food 624 
Safety Authority (EFSA) or the European Medicines Authority (EMA). Duplication of effort 625 
across different EU Member States could be averted through the systematic collection of 626 
research data across Europe, and promotion of collaboration among existing research 627 
groups to maximise efficiency and the development of common research portfolios. When 628 
applicable, the specialisation of particular research teams with a common sharing of 629 
resources might be relevant, in particular within the pharmaceutical sector in the production 630 
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of GM animals that improve the drug innovation process (e.g., disease models). 631 
Researchers should be encouraged to consider the minimum number of animals required for 632 
a study and whether existing GM animals could be used instead of developing a new GM 633 
animal line, in line with existing 3Rs policy (i.e. reduction, refinement, and replacement) of 634 
animal use in research [87]. Such policies may also be relevant internationally. The 635 
pharmaceutical industry and medical sector generally should be encouraged to collaborate 636 
in the development of strategies to enable the benefits of pharmaceutical innovation to be 637 
delivered, perhaps through establishing private-public partnerships.  638 
 639 
With respect to governance, stakeholders indicated that the EU should maintain its effort to 640 
harmonise regulation. Where regulatory implementation is difficult (e.g., the GMO comitology 641 
procedure - see [88]), procedural changes should be explored. For example, inclusion of 642 
socio-economic factors in the European comitology procedure would potentially improve the 643 
transparency of dialogue with stakeholders and, consequently, the discussion between 644 
national competent authorities. Advisory bodies such as EFSA only report on the scientific 645 
risks of a given GM animal; and empowering institutions to provide information on the 646 
possible benefits, in addition to the possible risks, in their assessments (including GM animal 647 
applications) is important in the facilitation of innovation processes. Such changes in 648 
regulation within Europe would, of course, need to remain sensitive to the international 649 
context (i.e. WTO) and where appropriate work towards global harmonisation of regulations. 650 
 651 
The need to involve the public in the debate about implementing and commercialising GM 652 
animals and their products is recognised, and public engagement mechanisms such as the 653 
citizens’ jury, and other deliberative processes, will potentially represent a useful approach to 654 
fine-tuning policy relating to GM animals. The ‘deliberative space’ created by the citizens’ 655 
jury methodology facilitates the kind of group interaction and depth of discussions needed to 656 
inform policy. However, a more geographically extensive application of the methodology is 657 
required, in order to include differences in countries and regions with different socio-658 
historical approaches to technology regulation, and allow comparative analysis between 659 
these. The approach is better suited to the discussion of pre-formulated and realistic policy 660 
scenarios or options which are compatible with existing systems of policy making. For 661 
example, if the results are to be used explicitly to assess the relative merits of different policy 662 
outcomes or alternatives, these need to be translated from scientific outcomes to different 663 
policy options. An analysis of policy impact is needed in order to justify and optimise citizen 664 
engagement within the policy process. As a de minimis, the process by which such policy 665 
outputs are anticipated to have an impact on local, national, regional or international policy 666 
should be described, both in terms of process (i.e. how is the information to be translated 667 
and delivered to decision-makers) and practice (i.e. what is the impact of such information 668 
on the policy process). This is in line with current thinking regarding the impacts of other 669 
forms of consultation on policy processes, for example in the context of expert consultations 670 
[89]. 671 
 672 
Conclusions  673 
The results have delivered data relevant to support policy with the development of an 674 
innovation strategy, taking into account the range of issues associated with GM animals from 675 
a life and social science perspective. As for any emerging area of technology, potential risks 676 
and benefits can be identified, and, in the case of GM animals, the evidence suggests that 677 
these require a case-by-case analysis. This is demonstrated by the different issues raised by 678 
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the three case studies (Table 2) and the extrapolation to other examples of GM animals 679 
currently under development (Table 3).  680 
………………… 681 
Table 3 about here 682 
…………………… 683 
One issue is that, as a result of the research being conducted by a European research 684 
consortium, with the aim of supporting European Policy development, many major events, 685 
works and issues that have emerged in the US have not been addressed. Discussion of 686 
these is beyond the scope of the current paper, and indeed these have been discussed 687 
extensively elsewhere (e.g., see [90]). However, the international dimension merits further 688 
analysis in a global policy context, in particular in relation to regulatory harmonisation. A 689 
deciding factor regarding whether, and under what conditions, GM animals are to be 690 
introduced and commercialised will be societal acceptance, which will be contingent not only 691 
on risk perceptions or other value-based attitudes, but also the perceived benefits offered by 692 
specific applications. The issue of consumer choice (and implementation of effective 693 
traceability and labelling strategies) will also be important, in particular in relation to agri-food 694 
applications. In addition, equitable distribution of socio-economic benefits between 695 
producers and consumers, and between affluent and disadvantaged countries and regions is 696 
important.  697 
 698 
Assuming appropriate risk assessments have been conducted (including those related to 699 
animal welfare and the impact of environmental release and/or escape), there appears to be 700 
little evidence that the introduction of GM animals for pharmaceutical production will be 701 
problematic from a societal perspective. Developing applications of GM animals for food use 702 
will be successful only if benefits align with public preferences. Communication about, and 703 
public engagement with, emerging policy is important, providing the goals of such activities 704 
are well thought through and the policy impact of such public engagement activities are 705 
explicitly assessed. In addition, harmonisation of European research activities is an 706 
important priority to avoid duplication of effort and unnecessary sacrifice of animals, as is 707 
global harmonisation of regulatory activities regarding international trade and development.  708 
  709 
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 Case study  Type  Method  Driving forces  Type of experts’ consultation  Scenarios identified  
Growth-Enhanced 
GH Transgenic 
Salmon  
Qualitative and 
quantitative  
Cross-impact 
analysis  logic-
verbal technique  
Production and firm-
based cost model  
15 driving forces divided in 4 categories:  
1) Production  
2) Market  
3) Public/Consumption  
4) Regulatory framework  
Questionnaire web + telephone 
interviews  
A- GM fish banned  
B - GM salmon for dinner  
C - GM salmon doesn‘t take 
off  
Recombinant 
Human Lactoferrin 
(rhLf) in the Milk of 
Transgenic Cows  
Qualitative  Intuitive logic 
Focused interview 
(structured 
questionnaire with 
open ended 
questions)  
Main driving forces:  
1) cost-effectiveness  
2) human health  
Other relevant driving forces:  
1) Production  
2) Market  
3) Consumer/producer Acceptance  
4)  Regulatory framework  
Questionnaire+ Face to face , 
telephone, e-mail interview  
A-rhLf adopted outside the 
EU  
B- rhLf adopted also in the 
EU  
C- rhLf is not adopted 
worldwide  
Polyclonal 
Antibodies (pAbs) 
from Transgenic 
Rabbits  
Qualitative  Intuitive logic with 
personal interview 
and structured 
questionnaire  
Driving forces are:  
1)  Proprietary knowledge and patents  
2)  Public  policy  
3)  Consumer behaviour  
4)  Risk factors  
Direct and indirect contacts of 
different stakeholders (personal 
interview)+  
Structured questionnaire  
 e-mails  
A - pAbs from GM Rabbits a 
reality with limited access  
B - pAbs from GM animals 
unrealistic  
C - pAbs from GM rabbits 
may take off with wider 
access  
 
Table 2 . Scenario analysis settings for the three case studies 
 Genetically 
modified animal 
under 
consideration  
Advantages from a 
life science 
perspective  
Disadvantages 
from a life 
science perspective 
Advantages from 
an economics  
perspective  
  
 
Disadvantages 
from an economic 
perspective 
Public/citizen 
perceptions 
 
Ethical aspects  
Transgenic Salmon with 
increased growth rate 
and/or increased disease 
and stressor resistance  
-Improved human nutrition 
(increased availability of 
omega-three fatty acids ) 
-Potential for improved - 
resistance to 
environmental stressors 
and pathogens  
-Potential for the 
introduction of allergens 
into the human food chain 
-Strong environmental 
impact potential (although 
data suggest this is not the 
case if containment is 
sufficient) * 
-100% sterility not 
achievable  
-Increased gross margins 
(profits) for producers 
-Reduction of retail prices 
for consumers  
-Costs of producing safety 
dossiers / claims dossiers 
for regulators will be high 
and bourn by the industry  
- 
-Increased costs from 
building aquatic 
containment facilities  
-Increased dependency of 
farmers from suppliers  
-Negative impacts on 
SMEs 
-Labelling and traceability 
required 
-Equity of distribution of 
benefits to different 
countries and across 
populations needs to be 
considered 
-Transgenic fish more 
acceptable than 
transgenic terrestrial  
animals applied to food 
production  
-Consumer benefits need 
to be concrete and visible 
(i.e. reduced cost) 
-Non-medical applications 
are less acceptable 
-Effective labelling, 
traceability and animal 
welfare policies essential 
for consumer acceptance  
-Welfare issues not well 
defined 
-Alternative technologies 
need to be considered  
-Effective labelling and 
traceability policies 
essential for consumer 
choice  
-Socio-economic impacts 
(e.g. negative impacts on 
small producers) need to 
be considered 
-benefits for developing 
countries not well defined  
-Labelling and traceability 
required to preserve 
consumer autonomy 
- Does the application 
delivery increased global 
food security or only 
reduce price for developed 
countries?  
- 
Transgenic cattle  produce 
lactoferrin in milk, for use 
in infant formula 
-Improved human nutrition 
(infant formula ) 
-Appropriate species to 
produce large amounts of 
protein for human 
consumption  
-Generation through 
cloning or lentiviral vectors 
-Slow reproduction 
-Susceptible to prion 
diseases  
-Reduction in agro-
biodiversity  
-Slow rate of reproduction 
reduces efficiencies in the 
supply chain 
-Costs of producing safety 
dossiers / claims dossiers 
for regulators will be high 
and bourn by the industry 
-Economic efficiencies in 
production chain  
 
-Potentially high margins if 
public assume that this is 
a medical product and/or a 
functional food 
-Labelling and traceability 
required to preserve 
consumer autonomy 
-Equity of distribution of 
benefits to different 
countries and across 
populations needs to be 
considered 
-Potentially higher 
acceptance if perceived as 
medical application 
-Product designed for 
consumption by infants 
may trigger concerns 
-perceived potential to 
introduce  of prion 
diseases to human food 
chain 
-Further case study based 
analysis required  
-Animal welfare issues 
associated with 
reproduction, quality of life 
etc  
-Alternative production 
options may be available,  
-Labelling and traceability 
required to preserve 
consumer autonomy 
 
Rabbits modified to 
produce polyclonal oclonal 
antibodies (pAbs) for 
human therapeutics  
-PABs produced using 
genetically modified 
animals have high titers 
-Note polyclonal 
antibodies produced using 
GM animals may be 
associated with increased 
immunogenicity 
-Relatively high rate of 
reproduction  
- Requirements for special 
feeding and restricted 
rearing conditions 
-Equity of distribution of benefits to different countries 
and across populations may involve knowledge transfer 
and capacity building  
-The production cost is expected to be acceptable for 
treatment of patients. At the present time, alternative 
methods are not available as the only available human 
pABs come from immunized persons. 
-Other candidate producer animals (pigs and cows) will 
occur.  
- If a clear need is 
established,  acceptance 
is likely to be high as this 
will be perceived as a 
medical application 
-Little data available 
regarding consumer 
preferences for 
pharmaceutical labelling 
but stakeholders suggest 
this will be required. -
Labelling and traceability 
-Limited data regarding 
animal welfare 
-Large numbers of animals 
required means high 
levels of animal sacrifice 
-Alternative technologies 
may be available if 
research is resourced.  
is also establish for 
pharmaceutical 
applications 
Table 1. Summary of the issues raised by the GM animal cases.  
* Le Curieux-Belfond, O., Vandelac, L., Caron, J., and  Séralini, G. É. (2009). Factors to consider before production and commercialization of aquatic genetically modified 
organisms: the case of transgenic salmon. Environmental Science & Policy, 12(2), 170-189. See also Van Eenennaam and Muir, 2011 [51) in reference list. 
 Category Application time scale Examples Ethical issues Economic issues Public perception and 
attitude 
Results of citizens' juries Policy Life science 
Benefits 
Life science risks Research needs Comments 
Disease models The most common form of 
GM animal currently used  
Rodents, rabbits and pigs 
used to 
- Model human diseases 
- Test therapeutics 
-Animal welfare issues 
associated with the high 
numbers of animals 
sacrificed, such as 
duplication of effort  
-Animal alternatives may be 
feasible 
-Ethical requirement to 
reduce animal and human 
suffering associated with 
disease  
- Cost is reducing enabling 
larger animals to be used 
as more accurate models  
 
-Generally  positive as 
medical benefits are both 
tangible and desirable 
Medical research is 
essential, although 
improved animal welfare 
and reduced animal 
sacrifice required if possible 
(e.g. through elimination 
duplication of effort across 
the EU) 
-Duplication of effort in 
research capacity across 
Europe suggest the need 
for harmonisation of 
research activities 
 
-Acceleration of medical 
research  
-Risk of unintended 
environmental release not 
well understood 
-Animals kept in confined 
areas 
-Can alternatives to the 
development of animal 
models be identified? 
An established area of 
application 
Bioreactors 
-GM animals producing 
therapeutics in their milk 
or eggs 
Application is current, less 
advanced or extensive  
than animal disease 
models 
Current examples include 
Atryn (goat),  
Rhucin or Ruconest  
(rabbits) 
-Animal welfare issues 
associated with the high 
numbers of animals 
sacrificed and  
technique. -Alternative 
approaches may be 
feasible 
-Will all citizens , including 
those in developing 
countries, have equitable 
access to products?  
 
-Pharmaceutical 
Industry “buy-in” is poor 
owing to IPR concerns  
- Cost of pharmaceutical 
products could reduce for 
the consumer 
-potential advantages for 
poorer countries assuming 
capacity building is 
adequate  
  
-Positive regarding 
pharmaceutical production 
-Ethical and religious 
objections are not severe 
but could potentially arise  
 
-Medical research 
important but are 
alternative approaches 
available? 
Improved Animal and 
reduced animal sacrifice 
are important if possible. 
Labelling and traceability 
systems required to support 
informed choice.  
-Public financial support 
essential 
-Public-private partnerships 
should be encouraged 
-Knowledge transfer to 
developing countries a 
priority  
--At the present time, 
production costs (and 
hence retail costs) are in 
gen ral  not reduced by 
utilisation of genetically 
modified animals, although 
exceptions can be 
identified. 
-. Uptake by 
pharmaceutical sector is 
limited because of 
concerns about 
competition. 
 
-Increased rate of 
pharmaceutical production 
should improve public 
health 
-Some proteins (e.g. 
Human Albumin) can only 
be produced in sufficient 
amounts by use of GM 
animals or plants  
-Introduction of unintended 
health risks 
-Unintended release into 
the environment may have 
uncertain impacts, in 
particular for high profligacy 
species 
 
-Consumer research 
needed to understand if 
pharmaceutical products 
derived from GM animals 
would be labelled as such?  
-More data is needed 
regarding animal welfare 
issues  
-Should diseases of poverty 
be a greater focus of 
research? 
 
Animals genetically 
altered to improve foods  
Application is current, but 
not commercialised widely 
(for example, no 
applications are licenced in 
Europe or North America.  
Aquabounty Salmon 
-Environpig (research 
transferred from Canada to 
China)   
 
-Animal welfare issues 
need to be examined and 
contextualised by 
comparison with production 
systems  
-Animal welfare may be 
improved in some cases 
(fro example, through 
increased resistance to 
diseases)  
-Are the benefits 
substantial enough to justify 
the concerns  
-Efficiency in the production 
chain much lower than for 
pharmaceutical applications  
-GM Labelling essential if 
commercialisation is to be 
successful 
-Consumer prices will 
reduce  
-Potential threats to SMEs 
and smaller producers 
-Generally negative but 
each case should be 
examined with respect to 
potential benefits 
-Perceptions are species 
dependent (Transgenic fish 
are more acceptable than 
terrestrial  animals)  
-Not clear whether 
nutriceuticals will be 
perceived as medicine or 
foods.  
-GM Labelling essential  
-Generally negative as little 
perceived need for food 
related applications and 
lack of clarity over the 
possible benefits it would 
deliver to the end 
consumer, but more 
positive for cases 
associated with the cases 
which boarder food and 
medical/pharmaceutical 
application 
-Where clear ‘need’ and 
concrete benefits could be 
demonstrated, acceptability 
of agri-food applications 
may rise.  
-Risk-benefit assessment 
required 
-Assessment of socio-
economic and ethical 
issues, as well as health 
and environmental impacts, 
required within risk analysis 
process.  
-Improved public health 
through improved nutrition 
and food security 
 
-Reduced or  increased 
agribiodiversit eith unknown 
impacts.  
-products may not meet the 
demands of societal 
challenges as claimed (e,g, 
food security)  
-More data needed 
regarding perceptions of 
consumer in the BRIC 
countries 
-Societal attitudes 
developing countries not 
well understood 
-Consumer inputs into the 
design of beneficial food 
products will facilitate  their 
introduction 
The initial introduction of 
foods derived from GM 
animals may crystallise 
attitudes although this will 
be dependent on the 
perceptions of benefit 
associated with these 
applications 
-Given the greater level of 
public concern, public 
engagement in policy 
development and product 
design  may be more 
appropriate for food-related 
applications of GM animals.  
 
 
Table 2. Summary table -The issues for GM animals. Despite attempts to extrapolate broad policy issues to different category of application, it is important that a case-by case approach to regulation is applied. This table seeks to highlight issues which may be of particular relevance to the 
different categories. The table highlights prominent applications, but it excluded the use of genetically modified animals to produce organs for xenotransplantation as such applications were not systematically in the analysis conducted within this work. Similarly companion animals were not 
included. Note that for both Xenotransplantation and genetically modified companion animals there is little data regarding either the economic advantages and disadvantages, nor public perceptions of the risks and benefits.  
 
 
